Market Overview

UPDATE: Goldman Sachs Reduces PT to $16 on NuVasive on Sales Outlook

Share:
Related NUVA
Piper Jaffray Met With NuVasive Management And Came Away 'Still Confident'
Goldman Sachs' New Pair Trade? Bull Zeltiq Aesthetics, Bear NuVasive
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

Goldman Sachs reiterated its Neutral rating on NuVasive (NASDAQ: NUVA) and lowered its price target from $17 to $16.

Goldman Sachs commented, "NUVA shares reacted well to earnings (+12% mid-day vs. the Russell 2000 -0.2%), on management initiatives to reverse negative share trends (the stock was down 44% since the 10/3 pre-announcement as of the 10/23 close, vs -3% for the Russell 2000). Early trends are favorable, with new account capture already realized. It will, however, take time for new reps to ramp productivity, deferring a material improvement in overall sales growth; this is reflected in our revised model that calls for +1% in 1H13 and +9% in 2H13."

NuVasive closed at $12.65 on Tuesday.

Latest Ratings for NUVA

DateFirmActionFromTo
Jul 2015Brean CapitalMaintainsBuy
Jul 2015Northland SecuritiesUpgradesMarket PerformOutperform
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for NUVA
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (NUVA)

Get Benzinga's Newsletters